Logo image of CARL

CARLSMED INC (CARL) Stock Fundamental Analysis

USA - NASDAQ:CARL - US14280C1053 - Common Stock

12.19 USD
-0.12 (-0.97%)
Last: 11/18/2025, 2:25:51 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CARL. CARL was compared to 188 industry peers in the Health Care Equipment & Supplies industry. The financial health of CARL is average, but there are quite some concerns on its profitability. CARL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CARL has reported negative net income.
CARL Yearly Net Income VS EBIT VS OCF VS FCFCARL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of -93.29%, CARL is doing worse than 77.66% of the companies in the same industry.
CARL has a worse Return On Equity (-193.71%) than 71.28% of its industry peers.
Industry RankSector Rank
ROA -93.29%
ROE -193.71%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CARL Yearly ROA, ROE, ROICCARL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2023 2024 0 500 1K

1.3 Margins

The Gross Margin of CARL (36.90%) is worse than 68.62% of its industry peers.
The Profit Margin and Operating Margin are not available for CARL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 36.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CARL Yearly Profit, Operating, Gross MarginsCARL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024 0 -50 -100

More info and screens

5

2. Health

2.1 Basic Checks

CARL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CARL has about the same amount of shares outstanding.
CARL has a better debt/assets ratio than last year.
CARL Yearly Shares OutstandingCARL Yearly Shares OutstandingYearly Shares Outstanding 2023 2024 5M 10M 15M 20M 25M
CARL Yearly Total Debt VS Total AssetsCARL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

An Altman-Z score of 3.77 indicates that CARL is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.77, CARL is in the better half of the industry, outperforming 74.47% of the companies in the same industry.
A Debt/Equity ratio of 0.60 indicates that CARL is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.60, CARL is not doing good in the industry: 63.83% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Altman-Z 3.77
ROIC/WACCN/A
WACC8.6%
CARL Yearly LT Debt VS Equity VS FCFCARL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2023 2024 0 20M -20M -40M

2.3 Liquidity

A Current Ratio of 4.87 indicates that CARL has no problem at all paying its short term obligations.
CARL has a better Current ratio (4.87) than 78.72% of its industry peers.
CARL has a Quick Ratio of 4.76. This indicates that CARL is financially healthy and has no problem in meeting its short term obligations.
CARL has a Quick ratio of 4.76. This is amongst the best in the industry. CARL outperforms 84.04% of its industry peers.
Industry RankSector Rank
Current Ratio 4.87
Quick Ratio 4.76
CARL Yearly Current Assets VS Current LiabilitesCARL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for CARL have decreased strongly by -31.49% in the last year.
Looking at the last year, CARL shows a very strong growth in Revenue. The Revenue has grown by 97.16%.
EPS 1Y (TTM)-31.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)97.16%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CARL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.48% yearly.
The Revenue is expected to grow by 27.10% on average over the next years. This is a very strong growth
EPS Next Y-45.31%
EPS Next 2Y8.24%
EPS Next 3Y6.23%
EPS Next 5Y8.48%
Revenue Next Year-12.4%
Revenue Next 2Y12.26%
Revenue Next 3Y21.95%
Revenue Next 5Y27.1%

3.3 Evolution

CARL Yearly Revenue VS EstimatesCARL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 50M 100M
CARL Yearly EPS VS EstimatesCARL Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CARL. In the last year negative earnings were reported.
Also next year CARL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CARL Price Earnings VS Forward Price EarningsCARL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CARL Per share dataCARL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.24%
EPS Next 3Y6.23%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CARL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARLSMED INC

NASDAQ:CARL (11/18/2025, 2:25:51 PM)

12.19

-0.12 (-0.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)N/A N/A
Inst Owners0.55%
Inst Owner ChangeN/A
Ins Owners10.78%
Ins Owner Change20.2%
Market Cap324.01M
Revenue(TTM)54.33M
Net Income(TTM)-49.70M
Analysts85.45
Price Target18.77 (53.98%)
Short Float %2.71%
Short Ratio4.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-19.84%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.96
P/FCF N/A
P/OCF N/A
P/B 12.63
P/tB 12.63
EV/EBITDA N/A
EPS(TTM)-1.87
EYN/A
EPS(NY)-1.55
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS2.04
BVpS0.97
TBVpS0.97
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -93.29%
ROE -193.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 36.9%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover1.02
Health
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.87
Quick Ratio 4.76
Altman-Z 3.77
F-ScoreN/A
WACC8.6%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-45.31%
EPS Next 2Y8.24%
EPS Next 3Y6.23%
EPS Next 5Y8.48%
Revenue 1Y (TTM)97.16%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-12.4%
Revenue Next 2Y12.26%
Revenue Next 3Y21.95%
Revenue Next 5Y27.1%
EBIT growth 1Y-29.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.43%
EBIT Next 3Y11.76%
EBIT Next 5Y14.45%
FCF growth 1Y-45.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-45.69%
OCF growth 3YN/A
OCF growth 5YN/A

CARLSMED INC / CARL FAQ

What is the ChartMill fundamental rating of CARLSMED INC (CARL) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CARL.


What is the valuation status for CARL stock?

ChartMill assigns a valuation rating of 0 / 10 to CARLSMED INC (CARL). This can be considered as Overvalued.


How profitable is CARLSMED INC (CARL) stock?

CARLSMED INC (CARL) has a profitability rating of 0 / 10.


What is the financial health of CARLSMED INC (CARL) stock?

The financial health rating of CARLSMED INC (CARL) is 5 / 10.


Can you provide the expected EPS growth for CARL stock?

The Earnings per Share (EPS) of CARLSMED INC (CARL) is expected to decline by -45.31% in the next year.